An orally available non-nucleotide STING agonist with antitumor activity-Reference-Cited by-同舟云学术

An orally available non-nucleotide STING agonist with antitumor activity

Published:2020-08-21 Issue:6506 Volume:369 Page:
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Pan Bo-Sheng¹^ORCID,Perera Samanthi A.¹^ORCID,Piesvaux Jennifer A.¹^ORCID,Presland Jeremy P.¹^ORCID,Schroeder Gottfried K.¹^ORCID,Cumming Jared N.²^ORCID,Trotter B. Wesley²^ORCID,Altman Michael D.²,Buevich Alexei V.²^ORCID,Cash Brandon²^ORCID,Cemerski Saso³^ORCID,Chang Wonsuk²^ORCID,Chen Yiping¹,Dandliker Peter J.¹^ORCID,Feng Guo¹^ORCID,Haidle Andrew²^ORCID,Henderson Timothy²,Jewell James²,Kariv Ilona¹,Knemeyer Ian⁴^ORCID,Kopinja Johnny¹^ORCID,Lacey Brian M.¹^ORCID,Laskey Jason¹^ORCID,Lesburg Charles A.²^ORCID,Liang Rui²^ORCID,Long Brian J.¹,Lu Min²^ORCID,Ma Yanhong¹,Minnihan Ellen C.⁵^ORCID,O’Donnell Greg¹^ORCID,Otte Ryan²^ORCID,Price Laura¹^ORCID,Rakhilina Larissa¹^ORCID,Sauvagnat Berengere¹^ORCID,Sharma Sharad³^ORCID,Tyagarajan Sriram²^ORCID,Woo Hyun⁴^ORCID,Wyss Daniel F.²^ORCID,Xu Serena¹,Bennett David Jonathan²^ORCID,Addona George H.¹^ORCID

Affiliation:

1. Department of Quantitative Biosciences, Merck & Co., Inc., Kenilworth, NJ, USA.

2. Department of Discovery Chemistry, Merck & Co., Inc., Kenilworth, NJ, USA.

3. Department of Discovery Oncology, Merck & Co., Inc., Kenilworth, NJ, USA.

4. Department of Pharmacokinetics, Merck & Co., Inc., Kenilworth, NJ, USA.

5. Department of Discovery Pharmaceutical Sciences, Merck & Co., Inc., Kenilworth, NJ, USA.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference39 articles.

1. Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies